{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:58:02Z","timestamp":1782140282472,"version":"3.54.5"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"DOI":"10.1186\/s13722-025-00638-y","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T02:53:42Z","timestamp":1766544822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Distilling the evidence for GLP-1 receptor agonists in alcohol use disorder"],"prefix":"10.1186","volume":"20","author":[{"given":"Eden Y.","family":"Bernstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Schacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"638_CR1","unstructured":"Global status report on alcohol and health and treatment of substance use disorders. Geneva: World Health Organization; 2024. License: CC BY-NC-SA 3.0 IGO."},{"issue":"17","key":"638_CR2","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","volume":"330","author":"M McPheeters","year":"2023","unstructured":"McPheeters M, O\u2019Connor EA, Riley S, et al. Pharmacotherapy for alcohol use disorder: A systematic review and Meta-Analysis. JAMA. 2023;330(17):1653\u201365. https:\/\/doi.org\/10.1001\/jama.2023.19761.","journal-title":"JAMA"},{"key":"638_CR3","doi-asserted-by":"publisher","unstructured":"Sinha B, Ghosal S. The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis. Addict Sci Clin Pract. 2025. https:\/\/doi.org\/10.1186\/s13722-025-00637-z.","DOI":"10.1186\/s13722-025-00637-z"},{"issue":"17","key":"638_CR4","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2016.16435","volume":"316","author":"DN Kyriacou","year":"2016","unstructured":"Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA. 2016;316(17):1818\u20139. https:\/\/doi.org\/10.1001\/jama.2016.16435.","journal-title":"JAMA"},{"issue":"4","key":"638_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","volume":"82","author":"CS Hendershot","year":"2025","unstructured":"Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry. 2025;82(4):395\u2013405. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.4789.","journal-title":"JAMA Psychiatry"},{"issue":"22","key":"638_CR6","doi-asserted-by":"publisher","first-page":"e170419","DOI":"10.1172\/jci.insight.170419","volume":"8","author":"L Probst","year":"2023","unstructured":"Probst L, Monnerat S, Vogt DR, et al. Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight. 2023;8(22):e170419. https:\/\/doi.org\/10.1172\/jci.insight.170419.","journal-title":"JCI Insight"},{"issue":"19","key":"638_CR7","doi-asserted-by":"publisher","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","volume":"7","author":"MK Klausen","year":"2022","unstructured":"Klausen MK, Jensen ME, M\u00f8ller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19):e159863. https:\/\/doi.org\/10.1172\/jci.insight.159863.","journal-title":"JCI Insight"},{"key":"638_CR8","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410. https:\/\/doi.org\/10.1136\/bmj-2023-076410.","journal-title":"BMJ"},{"issue":"9","key":"638_CR9","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1111\/add.15453","volume":"116","author":"CR Roos","year":"2021","unstructured":"Roos CR, Bold KW, Witkiewitz K, et al. Reward drinking and Naltrexone treatment response among young adult heavy drinkers. Addiction. 2021;116(9):2360\u201371. https:\/\/doi.org\/10.1111\/add.15453.","journal-title":"Addiction"},{"issue":"1","key":"638_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00213-024-06637-2","volume":"242","author":"A Fink-Jensen","year":"2025","unstructured":"Fink-Jensen A, W\u00f6rtwein G, Klausen MK, et al. Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male Vervet monkeys. Psychopharmacology. 2025;242(1):63\u201370. https:\/\/doi.org\/10.1007\/s00213-024-06637-2.","journal-title":"Psychopharmacology"},{"issue":"8","key":"638_CR11","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamapsychiatry.2021.1271","volume":"78","author":"B Han","year":"2021","unstructured":"Han B, Jones CM, Einstein EB, Powell PA, Compton WM. Use of medications for alcohol use disorder in the US: results from the 2019 National survey on drug use and health. JAMA Psychiatry. 2021;78(8):922\u20134. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.1271.","journal-title":"JAMA Psychiatry"},{"key":"638_CR12","doi-asserted-by":"publisher","unstructured":"Li P, Varghese JS, Shah MK, et al. Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity. JAMA Netw Open. 2025;8(10):e2540890. 2025 Oct 1. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.40890.","DOI":"10.1001\/jamanetworkopen.2025.40890"},{"issue":"3","key":"638_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MLR.0b013e3182408812","volume":"50","author":"GM Curran","year":"2012","unstructured":"Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs. Med Care. 2012;50(3):217\u201326. https:\/\/doi.org\/10.1097\/MLR.0b013e3182408812.","journal-title":"Med Care"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00638-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00638-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00638-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:31:11Z","timestamp":1769679071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-025-00638-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["638"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00638-y","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"24 December 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Schacht has served on a scientific advisory board for Apollo Therapeutics, has served as a consultant for SOURCE Bio, has received funding as a site principal investigator for a research study conducted by Altimmune, Inc., and has received study medication from Bausch Health for a different study. He is a member of the Alcohol Clinical Trials Initiative (ACTIVE), which is currently supported by Eli Lilly and Company, Imbrium Therapeutics, and Indivior Pharmaceuticals. Dr. Bernstein is a member of the Editorial Board for Addiction Science & Clinical Practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}